H. K. Kim

Gene expression signatures to predict the response of gastric cancer to cisplatin and fluorouracil.

A. Oshima, H. K. Kim, I. Choi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma.

H. K. Kim, M. Roh, H. Kwon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib

H. K. Kim, S. Ha, S-H. Jung, 2011, Blood cancer journal.

A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.

J. W. Kim, Y. Kim, H. K. Kim, 2010, Lung cancer.

Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer

H. K. Kim, H. Park, D. H. Kim, 2014, British Journal of Cancer.

Gene expression signatures associated with the resistance to imatinib

H. K. Kim, S. Ha, H. Namkoong, 2006, Leukemia.

Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy

A. Oshima, H. K. Kim, I. Choi, 2010, The Pharmacogenomics Journal.

Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor.

H. K. Kim, K. Ryu, S. Kim, 2003, European journal of cancer.

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma

H. K. Kim, Y. Kim, K. Ryu, 2006, British Journal of Cancer.

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma

H. K. Kim, K. Ryu, J. Lee, 2008, British Journal of Cancer.